Outstanding, eh?
This is the study we should have had years ago.
It says Pennsaid is NOT the same as other topicals. It's different. It's better.
Way better.
Ironic that the study should become public now.
The study emerges onto a whole new landscape for Dimethaid: the promised conventional PP seems to be in gear, and not at a much-feared price of 20 cents. This, in turn, will generate a stable price. It also means that immediate cash concerns are likely to be addressed.
The combined effect of the Vioxx/COX2 news, with the latest study is a multi-whammy: 2 pieces of positive news for the stock, accompanied by buying that easily outstripped the PP selling, on a day when 2.3 million shares moved.
It sure looks like a turning point. The sort of day we used to pray for. We all recognize that the outcome today is a synthesis of efforts by both old and new management.
Still, the impact of today's events would have been marginalized, a few months ago. Now, it's a whole new game.
There's no need to throw caution to the winds, but let's recognize what a significant day this has been for many shareholders.
There's more to come. Dimethaid appears to be finding its place in the sun.
Jim
|
